Acquire

Novo Nordisk to Acquire Dicerna for ~$3.3B

Shots: Novo Nordisk to acquire all outstanding shares of Dicerna common stock for $38.25/share in cash making a total equity value of ~$3.3B representing a premium of 80% to Dicerna’s closing price on Nov 17, 2021. The transaction is expected to close in the Q4’21 The acquisition will utilize Dicerna’s GalXC technology platform to expand …

Novo Nordisk to Acquire Dicerna for ~$3.3B Read More »

AcelRx to Acquire Lowell for ~$32.5M

Shots: AcelRx signs a merger agreement to acquire Lowell for $32.5M in cash and an additional ~$26.0M in contingent consideration upon the achievement of regulatory and sales-based milestones, $3.5M in AcelRx common stock, ~$6.5M is expected to be issued to Lowell security holders at closing. The transaction is expected to close in Q4’21 The acquisition …

AcelRx to Acquire Lowell for ~$32.5M Read More »

Organon to Acquire Forendo for ~$954M

Shots: Organon to acquire Forendo for a total consideration of $954M including $75M up front, $9M in Forendo debt, $270M upon the achievement of development & regulatory milestones & is eligible to receive $600M in commercial milestones payments. The transaction is expected to close in Dec’21 The acquisition adds a pipeline of products targeting novel …

Organon to Acquire Forendo for ~$954M Read More »

Coloplast to Acquire Atos Medical for ~$2.49B

Shots: Coloplast to acquire Atos Medical for an enterprise value of $2.49B from PAI Partners. The transaction is expected to close in Q2’22 Coloplast obtains access to a new chronic care segment to be run as a separate strategic business unit operating on shared Coloplast infrastructure that also supports its offerings in urology, continence and …

Coloplast to Acquire Atos Medical for ~$2.49B Read More »

Alcon to Acquire Ivantis for ~$475M

Shots: Ivantis to receive $475M up front along with additional payments upon achievement of regulatory & commercial milestones. The transaction is expected to close in Q1’22 The acquisition expands Alcon’s surgical portfolio & uses the commercial execution expertise across cataract, refractive, retina & glaucoma. Hydrus Microstent is approved for use in conjunction with cataract surgery …

Alcon to Acquire Ivantis for ~$475M Read More »

Lonza Collaborates with Codiak to Acquire its Exosomes Manufacturing Facility in Lexington, Massachusetts (US)

Shots: Codiak to receive $65M of in-kind manufacturing services for its clinical-stage programs and hold its pipeline of therapeutic candidates along with exosome engineering and loading technologies Lonza will obtain global access and sub-licensable rights of Codiak’s high-throughput perfusion-based cGMP process for exosome manufacturing The companies established a center of excellence to develop exosome manufacturing …

Lonza Collaborates with Codiak to Acquire its Exosomes Manufacturing Facility in Lexington, Massachusetts (US) Read More »

Takeda Signs an Agreement with Calithera to Acquire Sapanisertib and Mivavotinib

Shots: Takeda is eligible to receive $10M up front in addition to $35M in Calithera Series A preferred stock and is eligible to receive clinical development, regulatory, and sales milestone for both programs along with royalties The acquisition will bolster Calithera’s precision oncology pipeline of clinical-stage targeted therapies i.e., sapanisertib (TORC 1/2 inhibitor) and mivavotinib …

Takeda Signs an Agreement with Calithera to Acquire Sapanisertib and Mivavotinib Read More »

Hologic to Acquire Bolder Surgical for $160M

Shots: Hologic to acquire Bolder Surgical for ~$160M which is a provider of advanced energy vessel sealing surgical devices. The acquisition is expected to be closed by 2021 The transaction will add laparoscopic vessel sealing, dividing and dissecting devices to the Hologic portfolio and enable it to expand the use of Bolder’s devices to OB/GYN specialists The …

Hologic to Acquire Bolder Surgical for $160M Read More »

Pacira to Acquire Flexion for ~427M

Shots: Pacira Signs a definitive agreement to acquire Flexion for $8.50/share in cash along with one non-tradeable CVR of ~$8.00/share in cash upon the achievement of sales & regulatory milestones. The transaction is expected to close in Q4’21 The acquisition will support Pacira to expand its leadership position in non-opioid pain management with the addition …

Pacira to Acquire Flexion for ~427M Read More »

Boston to Acquire Baylis for ~$1.75B

Shots: Boston has entered into a definitive agreement to acquire Baylis for $1.75B up front. The transaction is anticipated to close in Q1’22 The acquisition will bolster Boston’s electrophysiology and structural heart product portfolios with the addition of Baylis’ platforms i.e., NRG and VersaCross Transseptal that uses radiofrequency to access the left side of the heart …

Boston to Acquire Baylis for ~$1.75B Read More »

Inotiv to Acquire Plato BioPharma for ~$15.0M

Shots: Inotiv to acquire Plato BioPharma for $15.0M that consist of $10.0M in cash, $2.0M in Inotiv’s common shares (57,587) based on the average closing price for 20 trading-day period ends on Sept 29, 2021, $3.0M in unsecured promissory notes The acquisition will bolster PBI’s growing discovery operations in the Boulder, Colorado & expands its …

Inotiv to Acquire Plato BioPharma for ~$15.0M Read More »

Merck to Acquire Acceleron for ~$11.5B

Shots: Merck to acquire Acceleron for $180/share in cash making a total equity value of ~$11.5B representing a premium of 2.6% to the stock’s closing price. The transaction is expected to close in Q4’21 The acquisition will strengthen Merck’s cardiovascular pipeline. Acceleron’s sotatercept is currently in P-III trials & has the potential to improve short-term …

Merck to Acquire Acceleron for ~$11.5B Read More »

AstraZeneca to Acquire Caelum for ~500M

Shots: Alexion has exercised its option to acquire all remaining equity in Caelum for CAEL-101 which is currently being evaluated in P-III CARES clinical program that consists of 2 P-III trials in combination with SoC therapy for AL amyloidosis Caelum to receive ~$150M as an option exercise fee in addition to ~$350M upon the achievement …

AstraZeneca to Acquire Caelum for ~500M Read More »

Boehringer Ingelheim Acquires Abexxa to Expands its Immuno-oncology Research

Shots: The acquisition includes upfront, milestones, and other consideration payments. Abexxa will continue to operate in the Arlington The acquisition will allow Boehringer to access Abexxa’s expertise and capabilities in targeting cancer-specific proteins by using its technology to develop cancer immunotherapies and Abs for solid cancers The acquisition also bolsters Boehringer’s commitment to identifying the …

Boehringer Ingelheim Acquires Abexxa to Expands its Immuno-oncology Research Read More »

Boston to Acquire Devoro for ~$336M

Shots: Boston currently holds ~16% equity stake in Devor & acquires the remaining 84% for ~$269M up front and ~$67M upon achievement of clinical & regulatory milestones. The transaction is expected to close in Q4’21 The acquisition will advance the peripheral interventions portfolio with the addition of Devoro’s WOLF thrombectomy platform to improve procedural efficiencies …

Boston to Acquire Devoro for ~$336M Read More »

ICU Medical Commits to Acquire Smith for ~$2.35B

Shots: Smiths to receive 2.5M at closing in cash and stock which is currently valued at ~$500M, $1.85B in cash along with liabilities & is eligible for up to $100M in milestones. The transaction is expected to close in H1’22 The acquisition combines Smiths’ business includes syringes, ambulatory infusion devices, vascular access & vital care …

ICU Medical Commits to Acquire Smith for ~$2.35B Read More »

Baxter in Talks to Acquire Hill-Rom for ~$10B

Shots: Baxter in talks to acquire Hill-Rom for ~$10B with $150/ share representing a premium of 13% to the stock’s closing price of $132.90. The acquisition is expected to be announced later this week The decision follows an earlier bid in which Hill-Rom had turned down Baxter’s previous offer of $144/ share with a total …

Baxter in Talks to Acquire Hill-Rom for ~$10B Read More »

Pfizer to Acquire Trillium for ~$2.26B

Shorts: Pfizer will acquire all outstanding shares of Trillium for $18.50/share in cash making a total equity value of $2.26B with 203.8% premium on the stock’s last closing price The acquisition will bolster Pfizer’s R&D capabilities & accelerates clinical development of Trillium’s SIRPα fusion proteins i.e., TTI-622 & TTI-621 that are currently in P-Ib/II trial …

Pfizer to Acquire Trillium for ~$2.26B Read More »

Verily Acquires SignalPath to Expand its Clinical Research Capabilities

Shots: The acquisition will bolster Verily’s clinical trial system and Baseline platform to improve the efficiency, costs in clinical trials & speed up it at research sites globally. It also collects patient data for site-based, hybrid, and decentralized clinical studies SignalPath’s platform leverages modern software architecture with a cloud-based platform to reduces fragmentation & advance …

Verily Acquires SignalPath to Expand its Clinical Research Capabilities Read More »

Amgen to Acquire Teneobio for ~$2.5B

Shots: Amgen to acquire all outstanding shares of Teneobio for $900M as up front and $1.6B in cash as contingent milestones to Teneobio equity holders. The transaction is expected to be closed in H2’21 The acquisition will boost Amgen’s abilities to develop innovative therapies and expand its portfolio with the addition of early-stage oncology assets …

Amgen to Acquire Teneobio for ~$2.5B Read More »

Eli Lilly to Acquire Protomer Technologies for ~$1B

Shots: Eli Lilly to acquire Protomer Technologies for ~$1B, with the achievement of future development and commercial milestones Earlier, Lilly led an equity investment in Protomer along with JDRF T1D fund that provides Lilly with 14% ownership of promotor and is currently acquiring the remaining shares of Protomer beyond the initial investment The acquisition will …

Eli Lilly to Acquire Protomer Technologies for ~$1B Read More »

Novo Nordisk to Acquire Prothena’s ATTR Amyloidosis Program for ~$1.2B

Shots: Prothena is eligible to receive ~$1.2B as development and commercial milestones including $100M as up front and near-term clinical milestones Novo Nordisk acquires Prothena’s subsidiary and gets WW rights to the IP and related rights of Prothena’s ATTR amyloidosis business and pipeline. Novo Nordisk will develop the P-II ready Ab PRX004 for ATTR cardiomyopathy …

Novo Nordisk to Acquire Prothena’s ATTR Amyloidosis Program for ~$1.2B Read More »

PerkinElmer to Acquire Immunodiagnostic Systems Holdings for ~$155M

Shots: PerkinElmer to acquire IDS in all cash transactions for ~$155M. The transaction is expected to be completed in Q3’21 The acquisition will allow PerkinElmer to foster its overall Diagnostics business and specifically its immunodiagnostics segment The acquisition will integrate PerkinElmer’s channel expertise and testing capabilities with IDS’ chemiluminescence products in endocrinology, autoimmunity, and infectious …

PerkinElmer to Acquire Immunodiagnostic Systems Holdings for ~$155M Read More »

Athenex to Acquire Kuur Therapeutics for ~$185M

Shots: Kuur will receive $70M up front primarily in Athenex common stock and is eligible to receive ~$115 M as a milestone at Athenex’s sole discretion in either cash or additional Athenex common stock (or a combination of both) The acquisition will expand Athenex’s cell therapy development capability with Kuur’s off-the-shelf engineered CAR-NKT platform and …

Athenex to Acquire Kuur Therapeutics for ~$185M Read More »

Avantor to Acquire Ritter and its Affiliates for ~$1.06B

Shots: Avantor to acquire Ritter and its affiliates in an all-cash transaction with an up front equity purchase price of ~ $1.06B along with additional payments following the achievement of milestones. The transaction is expected to be completed in Q3’21 The acquisition expands Avantor’s offering for diagnostic and drug discovery workflows The acquisition integrates Ritter’s …

Avantor to Acquire Ritter and its Affiliates for ~$1.06B Read More »

DiaSorin to Acquire Luminex for ~$1.8B

Shots: DiaSorin to acquire Luminex for $37.00/ share in an all-cash transaction, with 23% premium based on closing stock price of Luminex on 24 Feb, 2021, making a total equity value of $1.8B The acquisition will boost DiaSorin’s presence in the molecular diagnostics space in the US with the addition of Luminex’s molecular diagnostics multiplexing …

DiaSorin to Acquire Luminex for ~$1.8B Read More »

Microsoft to Acquire Nuance for ~$19.7B

Shots: Microsoft to acquire all outstanding shares of Nuance for $56.00/ share, making a total deal value of $19.7B in cash with a premium of 23% to Nuance closing price on Apr 09, including its net debt. The transaction is expected to close in 2021 The acquisition builds on Microsoft’s efforts to deliver new cloud …

Microsoft to Acquire Nuance for ~$19.7B Read More »

Sanofi to Acquire Tidal Therapeutics for ~$470M

Shots: Sanofi to acquire Tidal Therapeutics for $160M up front and ~ $310M following the achievement of certain milestones The acquisition will add Tidal’s innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas With its acquisition, Sanofi will further develop the technology platform to expand its research capabilities in immuno-oncology and …

Sanofi to Acquire Tidal Therapeutics for ~$470M Read More »

Hologic to Acquire Mobidiag for ~ $795M

Shots: Hologic to acquire Mobidiag for ~$795M which includes ~$714M in cash for Mobidiag’s equity and debt of $81M. The acquisition is expected to close in Q4’21 The acquisition will accelerate Hologic’s global footprints by enabling it to expand into the large, fast-growing acute care adjacency with a near-patient testing solution that offers ease of …

Hologic to Acquire Mobidiag for ~ $795M Read More »

Sorrento to Acquire ACEA Therapeutics for ~$488M

Shots: ACEA to receive up to ~$38M in shares of Sorrento common stock, $450M as additional payments upon the achievement of clinical & sales milestones along with 5 – 10% royalties based on annual sales of each product. The acquisition is expected to close in Q2’ 21 The acquisition includes Abivertinib, AC0058, AC0939, and ACEA’s …

Sorrento to Acquire ACEA Therapeutics for ~$488M Read More »

Immunai Acquire Dropprint Genomics to Expand its Target Discovery Capabilities

Shots: Immunai acquires the Dropprint Genomics and also expand its team with the hiring of new experts in immunology, single-cell technologies and machine learning The acquisition and the new hiring will advance the Immunai’s work in single cell functional genomics to support discovery, prioritization, and development of new therapies and drug combinations The acquisition happened …

Immunai Acquire Dropprint Genomics to Expand its Target Discovery Capabilities Read More »

Grifols Acquires Remaining 56% of GigaGen for ~$80M

Shots: Grifols acquires the remaining 56% share of GigaGen for $80M. The acquisition will add GigaGen’s pipeline of recombinant polyclonal Abs, including GIGA-2050 and boost Grifol’s portfolio if I-O therapies Earlier, in 2017, Grifols acquired a 44% stake in GigaGen, when the two companies collaborated to develop polyclonal antibodies under a $50M pact GIGA-2050 is …

Grifols Acquires Remaining 56% of GigaGen for ~$80M Read More »

Takeda to Acquire Maverick for ~$525M

Shots: Takeda exercised its option to acquire Maverick for up to $525M up front as well as development and regulatory milestones including Takeda’s current equity stake and Maverick debt. The acquisition is expected to finalize in Q1’21 The acquisition will expand Takeda’s I-O portfolio with the addition of two development candidates (MVC-101 & MVC-280) and …

Takeda to Acquire Maverick for ~$525M Read More »

Agilent to Acquire Resolution Bioscience for $695M

Shots: Resolution to receive $550M in cash at closing and ~$145M following the achievement of certain milestones. The transaction is expected to close in Apr’2021 The acquisition will expand Agilent’s capabilities in NGS-based cancer diagnostics and strengthen its position in precision oncology testing globally The acquisition will bring together Resolution’s noninvasive liquid biopsy platform that …

Agilent to Acquire Resolution Bioscience for $695M Read More »

Amgen to Acquire Five Prime for ~$1.9B

Shots: Amgen to acquire all of the outstanding shares of Five Prime for $38.00 /share in cash, representing an equity value of ~ $1.9B. The transaction is expected to close in Q2’21 The acquisition will add Five Prime’s innovative pipeline to Amgen thus expanding its oncology portfolio and supports its international expansion strategy Five Prime’s …

Amgen to Acquire Five Prime for ~$1.9B Read More »

Boston Scientific Signs an Agreement with BPEA to Acquire Lumenis’ Surgical Business

Shots: Boston Scientific to acquire the global surgical business of Lumenis for $1.07B as an up front in cash. The transaction is expected to be completed in H2’21 BPEA will retain ownership of the Lumenis global aesthetics and ophthalmology businesses. The acquisition will expand Boston Scientific’s global kidney stone management portfolio and will expand its …

Boston Scientific Signs an Agreement with BPEA to Acquire Lumenis’ Surgical Business Read More »

Fusion to Acquire Ipsen’s IPN-1087 to Expand its Pipeline of Radiopharmaceuticals

Shots: Ipsen to receive 400,000 shares at closing and an additional 200,000 shares as milestones, $81.63M as development and regulatory milestones & $423.24M as commercial milestones along with royalties on net sales Fusion will be responsible for paying to a third-party licensor up to $84.7M in development milestones and royalties on net sales of products …

Fusion to Acquire Ipsen’s IPN-1087 to Expand its Pipeline of Radiopharmaceuticals Read More »

AbbVie Signs a Purchase Right Agreement to Acquire Mitokinin

Shots: Mitokinin to receive an up front and will continue to develop its PINK1 activator program through completion of IND enabling studies for its lead compound. If IND-enabling studies are successful, AbbVie will have the option to acquire Mitokinin The focus of the agreement is to advance Mitokinin’s PINK1 activator program to treat PD Mitokinin’s …

AbbVie Signs a Purchase Right Agreement to Acquire Mitokinin Read More »

Hologic to Acquire Diagenode for ~$159M

Shots: Hologic to acquire Diagenode for ~$159M. The transaction will expand and diversifies Hologic’s diagnostic business across test menu, customer segments and geography The acquisition will strengthen Hologic’s molecular diagnostics business by expanding international its capabilities and allow it to offer a broader more differentiated test menu Diagenode and Hologic previously collaborated to develop Hologic’s …

Hologic to Acquire Diagenode for ~$159M Read More »

Roivant to Acquire Silicon Therapeutics for ~$450M

Shots: Roivant to acquire Silicon for $450M in Roivant’s equity with additional potential regulatory and commercial milestones. The acquisition will strengthen Roivant’s AI capabilities for drug discovery The acquisition of Silicon will bolster Roivant’s targeted protein degradation platform that will be powered by VantAI’s ML techniques The integration of Silicon and VantAI will allow Roivant …

Roivant to Acquire Silicon Therapeutics for ~$450M Read More »

Merck to Acquire Pandion for ~$1.85B

Shots: Merck to acquire all outstanding share of Pandion for $60/share in cash, representing the equity value of ~$1.85B. The transaction is expected to close in H1’21 The acquisition will strengthen Merck’s portfolio with the addition of candidates targeting a broad range of autoimmune diseases Pandion is advancing a pipeline of precision immune modulators targeting …

Merck to Acquire Pandion for ~$1.85B Read More »

Novartis to Acquire GSK’s Cephalosporin Antibiotics Business

Shots: GSK to receive $350M at closing, along with ~$150M as milestones. The transaction is expected to close in H2’21 The transaction will allow GSK to prioritize and simplify its portfolio and invest in the company’s R&D pipeline and new product launches The agreement includes the global rights to three established brands (Zinnat, Zinacef and …

Novartis to Acquire GSK’s Cephalosporin Antibiotics Business Read More »

Jazz to Acquire GW Pharmaceuticals for $7.2B

Shots: Jazz to acquire GW Pharmaceuticals for $220/ GW ADS, out of which $200 in cash and $20 in Jazz ordinary shares, making a total deal value $7.2B with a 50% premium over a GW’s closing stock price on Feb 2, 2021. The transaction expected to close in Q2’21 The acquisition will expand Jazz’ neuroscience …

Jazz to Acquire GW Pharmaceuticals for $7.2B Read More »

Horizon Therapeutics to Acquire Viela Bio for ~ $3.05B

Shots: Horizon to acquire Viela Bio for $53/ share, representing an equity value of $3.05B with a 53% premium over a closing price to Viela’s on Jan 29, 2020. Additionally, AstraZeneca to divest its 26.7% ownership in Viela Bio in an exchange of ~$760 – $780M The transaction expected to close in Q1’21. The acquisition …

Horizon Therapeutics to Acquire Viela Bio for ~ $3.05B Read More »

Boston Scientific to Acquire Preventice for ~$1.2B

Shots: Boston Scientific to acquire Preventice for ~$1.2B including $925M as up front, up to an additional $300M as commercial milestones. However, Boston Scientific has built up a 22% stake in Preventice, which is expected to lower up front to $720M upfront & $230 million in milestone respectively The acquisition is expected to be close …

Boston Scientific to Acquire Preventice for ~$1.2B Read More »

Haemonetics to Acquire Cardiva Medical for ~$510M

Shots: Cardiva to receive $475M up front and up to an additional ~$35M in contingent consideration based on sales growth. The transaction is expected to be completed in Q1’21 The acquisition expands Haemonetics’ blood transfusion and loss management offerings and enhance its penetration into the large and growing interventional cardiology and electrophysiology markets Cardiva’s portfolio …

Haemonetics to Acquire Cardiva Medical for ~$510M Read More »

Thermo Fisher to Acquire Mesa Biotech for $450M

Shots: Thermo Fisher acquires Mesa Biotech for $450M in cash. Mesa Biotech will receive an additional ~$100M in cash on the completion of milestones while the transaction is expected to be completed in Q1’21 Mesa has developed & commercialized a PCR-based rapid POC testing platform for detecting infectious diseases. Messa’s technology inflates the availability of …

Thermo Fisher to Acquire Mesa Biotech for $450M Read More »

Philips to Acquire Capsule Technologies for ~$635M

Shots: Philips to acquire Capsule technologies for $635M in cash. The transaction is expected to be completed in H1’21 with the addition of ~300 employees of Capsule in Philips’ Connected Care segment The acquisition will expand Philips’ patient care management offering. The acquisition complements Philips’ strategy to transform the delivery of healthcare along the health …

Philips to Acquire Capsule Technologies for ~$635M Read More »

PharmaShots Weekly Snapshot (Jan 4-8, 2020)

Almirall and Tyris Collaborate to Develop Next Generation Gene Therapies Published: Jan 7, 2020 | Tags: Almirall, Tyris, Collaborate, Develop, Next Generation, Gene Therapies Sarepta Reports Mixed Results of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) in Part 1 of Study 102 for DMD    Published: Jan 7, 2020 | Tags: Sarepta, Reports, Mixed Results, SRP-9001, (rAAVrh74.MHCK7.micro-dystrophin), Part 1, Study 102, …

PharmaShots Weekly Snapshot (Jan 4-8, 2020) Read More »

PerkinElmer to Acquire Oxford Immunotec for ~$591M

Shots: PerkinElmer to acquire Oxford Immunotec for $22/ share with a premium of ~28.3% to the closing price/ share of $17.15 on Jan 5, 2021, making a total deal value $591M. The transaction is expected to be completed in H1’21 The acquisition allows the PerkinElmer to strengthen its portfolio of advanced infectious disease testing solutions …

PerkinElmer to Acquire Oxford Immunotec for ~$591M Read More »

Hologic to Acquire Biotheranostics for ~$230M

Shots: Hologic acquires Biotheranostics to speed up its entry in the oncology market. The transaction is expected to be completed in Feb’2021 The acquisition will provide Hologic access to Biotheranostics’ CLIA lab and will aid in accelerating market development for novel tests The acquisition allows Hologic to leverage commercial capabilities and expertise in molecular diagnostics …

Hologic to Acquire Biotheranostics for ~$230M Read More »

Hologic to Acquire Somatex for ~$64 M

Shots: Hologic acquired Somatex Medical Technologies for ~$64M. The acquisition of Somatex’s differentiated products will enable Hologic to strengthen & expand its breast marker portfolio The acquisition allows the company to expand its biopsy portfolio with the improvement in the biopsy experience for their patients. The acquisition provides Hologic additional expertise and capabilities to continue …

Hologic to Acquire Somatex for ~$64 M Read More »

Novartis to Acquire Cadent Therapeutics for ~$770M

Shots: Novartis to acquire all outstanding shares of Cadent for a total value of ~$770M. Cadent to receive $210M up front and is eligible for ~$560M as milestones. The transaction is expected to be close in Q1’21 Novartis gains full rights to Cadent’s NMDAr program which consist of two clinical programs: CAD-9303 and MIJ-821, an …

Novartis to Acquire Cadent Therapeutics for ~$770M Read More »

Lilly to Acquire Prevail Therapeutics for ~$1.04B

Shots: Lilly to acquire Prevail for $22.50/ share in cash (~ $880M) payable at closing plus one non-tradable CVR worth up to $4.00/ share in cash (~160M), making a total of $26.50/share in cash (~$1.040B). The transaction is expected to be close in Q1’21 The CVR is payable upon the first regulatory approval of a …

Lilly to Acquire Prevail Therapeutics for ~$1.04B Read More »

Gilead to Acquire MYR for ~$1.4B

Shots: Gilead to acquire MYR for ~$1.4B in the all-cash transaction along with ~$364.73M as a milestone upon the US FDA’s approval of Hepcludex (bulevirtide) The acquisition will provide Gilead with Hepcludex which has received EMA’s conditional approval for chronic HDV infection in adults with compensated liver disease in Jul’2020. MYR anticipates the submission for …

Gilead to Acquire MYR for ~$1.4B Read More »

AstraZeneca to Divest European Rights of Crestor (rosuvastatin) to Grünenthal for ~$350M

Shots: Grünenthal to acquire EU rights (Ex- Spain and the UK) of Crestor & its associated brands for ~$350M and will take over bulk production and packaging by 2025. The deal is expected to be closed in Q1’21 The payments will be made in two tranches: $320M will be paid upon transaction closing and $30M …

AstraZeneca to Divest European Rights of Crestor (rosuvastatin) to Grünenthal for ~$350M Read More »

Dr. Reddy’s to Divest Select Anti-Allergy brands to Dr. Reddy’s in Russia and Other CIS Countries

Shots: Dr. Reddy to acquire Glenmark’s brands Momat Rino (for Russia, Kazakhstan, and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan & Uzbekistan), Glenspray, and Glenspray Active (for Ukraine) along-with rights to the trademarks, dossiers, and patents for the mentioned territories The acquired products will further strengthen Dr. Reddy’s presence in the anti-allergy …

Dr. Reddy’s to Divest Select Anti-Allergy brands to Dr. Reddy’s in Russia and Other CIS Countries Read More »

Selvita to Acquire Fidelta from Galapagos for ~$37M

Shots: Selvita to acquire 100% of the outstanding shares in Fidelta for $37.08M + customary adjustments for net cash & working capital The acquisition will expand Selvita’s integrated drug discovery services offering with the addition of Fidelta Fidelta will be fully consolidated under Selvita Group & will continue to operate under the Fidelta name. Fidelta …

Selvita to Acquire Fidelta from Galapagos for ~$37M Read More »

Merck to Acquire OncoImmune for $425M

Shots: Merck to acquire all outstanding shares of Oncolmmune for $425 M in cash as an upfront. Additionally, Oncolmmune will receive sales-based and contingent payments on the achievement of the regulatory milestones The acquisition will give Merck control of CD24Fc which showed improvement in an interim efficacy analysis of a P-III study for the treatment …

Merck to Acquire OncoImmune for $425M Read More »

Novo Nordisk to Acquire Emisphere Technologies for $1.8B

Shots: Novo Nordisk to acquire all outstanding shares of Emisphere for $1.35B and also acquires royalty stream obligations to the firm’s biggest shareholder (MHR) for $450M, making a total deal value as $1.8B Novo Nordisk eliminates its future royalty obligations to Emisphere and MHR & obtains full access to the Eligen SNAC technology platform, thus …

Novo Nordisk to Acquire Emisphere Technologies for $1.8B Read More »

Merck to Acquire VelosBio for $2.75B

Shots: Merck will acquire all the outstanding shares of VelosBio for $2.75B in cash. The transaction is expected to be closed by the end of 2020 The acquisition will bolster Merck’s oncology pipeline with the addition of VelosBio’s VLS-101, which is an investigational ADC targeting ROR1 to treat hematological malignancies and solid tumors In Oct’2020, …

Merck to Acquire VelosBio for $2.75B Read More »

Novartis Acquires Vedere Bio for $280M

Shots: Vedere Bio received $150M as upfront payments and is eligible to receive up to $130M as milestones making a total deal value of $280M. The transaction closed in Sept’2020 The acquisition will strengthen Novartis’ footprints with the addition of lead preclinical intravitreally injected AAV gene therapy programs focused on pan-genotypic vision restoration in patients with …

Novartis Acquires Vedere Bio for $280M Read More »

Exact Sciences to Acquire Thrive Earlier Detection for ~$2.15B

Shots: Exact Sciences to acquire Thrive in all cash & stock transaction for ~2.15B out of which $1.7B would be payable at closing, consisting of 65% in Exact Sciences common stock and 35% in cash along with ~$450M as milestones related to the development and commercialization of a blood-based, multi-cancer screening test. The transaction is …

Exact Sciences to Acquire Thrive Earlier Detection for ~$2.15B Read More »

Endo to Acquire BioSpecifics for ~ $540M

Shots: Endo to acquire all the outstanding shares of BioSpecifics for $88.50/ share in cash, making a total deal value of $540M. The transaction is expected to close in late 2020 while Endo expects to fund the transaction with cash on hand BioSpecifics receives a royalty stream related to Endo’s collagenase-based therapies, which include Xiaflex …

Endo to Acquire BioSpecifics for ~ $540M Read More »

Eli Lily to Acquire Disarm Therapeutics for ~$1.36B

Shots: Lilly to acquire Disarm for $135M upfront and ~$1.225B as potential development regulatory and commercial milestones, making a total deal value of ~1.36B The acquisition will expand Lilly’s R&D efforts in pain and neurodegeneration with the addition of Disarm’s preclinical SARM1 programs for axonal degeneration Disarm is advancing its potent SARM1 inhibitors in preclinical …

Eli Lily to Acquire Disarm Therapeutics for ~$1.36B Read More »

BMS to Acquire MyoKardia for ~$13.1B

Shots: BMS to acquire all the outstanding shares of MyoKardia’s common stock for $225.00/ share in cash, making a total deal value of ~$13.1B. The transaction is expected to be close in Q4’20 The acquisition will foster BMS’ CV portfolio with the addition of MyoKardia’s mavacamten. BMS expects to explore mavacamten in additional indications, including …

BMS to Acquire MyoKardia for ~$13.1B Read More »

Philips to Acquire Intact Vascular for $360M

Shots: Philips will acquire Intact Vascular for $275M up front and deferred payments of $85M upon completion of the transaction. The transaction is expected to be completed in Q3’20 The collaboration will expand Philips’ image-guided therapy portfolio with the addition of Intact Vascular’s Tack endovascular system, that reinforces standard and drug-coated balloon PAD treatment results …

Philips to Acquire Intact Vascular for $360M Read More »

BMS to Acquire Forbius for its AVID200 to Expand its Footprints in Oncology and Fibrosis

Shots: Forbius will receive up front and milestones while BMS will acquire Forbius’s TGF-beta program, including the lead investigational asset, AVID200. The transaction is expected to be closed in Q4’20 Prior to closing, Forbius’ non-TGF-beta assets will be transferred to a newly formed private company, which will be retained by Forbius’ existing shareholders AVID200 is …

BMS to Acquire Forbius for its AVID200 to Expand its Footprints in Oncology and Fibrosis Read More »

Johnson & Johnson to Acquire Momenta Pharmaceuticals for $6.5B

Shots: J&J acquires Momenta in all-cash transaction at a price of $52.50/ share, making a total deal value as $6.5B. The transaction is expected to be closed in H2’20 The acquisition allows J&J to expand its portfolio for autoimmune diseases with the addition of Momenta’s Nipocalimab (M281) to its pipeline. In addition to nipocalimab, Janssen …

Johnson & Johnson to Acquire Momenta Pharmaceuticals for $6.5B Read More »

Sanofi to Acquire Principia Biopharma for ~$3.68B

Shots: Sanofi to acquire Principia Biopharma in an all-stock transaction, at $100/share making total deal value ~$3.68B in cash. The transaction is expected to be completed in Q4’20 The focus of the acquisition is to strengthen its R&D areas of autoimmune and allergic diseases with the expansion of the SAR442168 development program into CNS disorders. …

Sanofi to Acquire Principia Biopharma for ~$3.68B Read More »

Medtronic to Acquire Companion Medical for Adding Smart Insulin Pen to its Diabetes Unit

Shots: The acquisition will expand Medtronic’s capabilities to serve people using multiple daily injections (MDI) to manage diabetes with the addition of Companion Medical’s InPen to Medtronic’s portfolio. The acquisition is expected to be closed within 1-2mos. Medtronic will advance the automation of insights and dosing capabilities to reduce the burden of diabetic patients. Additionally, …

Medtronic to Acquire Companion Medical for Adding Smart Insulin Pen to its Diabetes Unit Read More »

Bayer to Acquire KaNDy Therapeutics for Augmenting its Women’s Healthcare Portfolio

Shots: KaNDy to receive $425M upfront, ~$450M milestones until launch followed by additional commercial milestones. The transaction is expected to be completed in Sept’2020 The acquisition will add KaNDy’s menopause drug to Bayer’s portfolio. KaNDy has published results of its NT-814 in P-IIb study that demonstrated positive results in mod. to sev. vasomotor symptoms due …

Bayer to Acquire KaNDy Therapeutics for Augmenting its Women’s Healthcare Portfolio Read More »

Olympus to Acquire Arc Medical Design for Expanding its Product Portfolio

Shots: The acquisition will expand Olympus’ offerings in GI therapeutic devices and the development of advanced colonoscopy tools with the aim of improving early detection and treatment of CRC Olympus will obtain full rights to Arc Medical Design’s medical products and will convert its current exclusive distribution rights of Endocuff Vision to a full acquisition …

Olympus to Acquire Arc Medical Design for Expanding its Product Portfolio Read More »

Siemens Healthineers to Acquire Varian for $16.4B

Shots: Siemens Healthineers to acquire Varian in an all-cash transaction, at a price of $177.50/ share with 42% to the 30-day volume-weighted average closing price of Varian’s common stock as of July 31, 2020, making a total deal value ~$16.4B The transaction is expected to be closed in H1’21. The combined company will offer an …

Siemens Healthineers to Acquire Varian for $16.4B Read More »

Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer

Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission targeted for Aug’2020. The transaction is expected to be close in Aug’2020. The integration of Sorrento’s G-MAB Ab library and SmartPharm’s GET platform is expected …

Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer Read More »

Gilead to Acquire Tizona’s Stakes for $300M

Shots: Gilead invests $300M to obtain 49.9% equity interest in Tizona and receives an exclusive option to acquire remaining stakes of Tizona for up to an additional $1.25B that includes an option exercise fee and milestones. The transaction is expected to be closed in Q3’20 Gilead can exercise its option following the results of a …

Gilead to Acquire Tizona’s Stakes for $300M Read More »

GSK to Acquire 10% stake in CureVac for $163M

Shots: GSK will invest $163M (€150m) in CureVac for a 10% stake to collaborate for the research, development, manufacturing, and commercialization of up to five mRNA-based vaccines and mAbs targeting infectious disease pathogens excluding CureVac’s existing COVID-19 mRNA and rabies vaccines research programs CureVac to receive $137M (€120m) as upfront, $34.3 (€30m) as one-time reimbursable …

GSK to Acquire 10% stake in CureVac for $163M Read More »

Thermo Fisher Scientific Amends its Agreement to Acquire QIAGEN

Shots: Under the amended agreement, the offer price increased from $44.5 to $49/QIAGEN share in cash, representing a premium of 35% to the closing price of QIAGEN’s ordinary shares on the Frankfurt Prime Standard on Mar 2, 2020, making the latest deal value as $12.5B The amendment also provides for a reduction of the minimum …

Thermo Fisher Scientific Amends its Agreement to Acquire QIAGEN Read More »

Kronos Bio to Acquire Gilead’s SYK Inhibitor Portfolio

Shots: Gilead to receive an up front in cash and convertible notes into Kronos equity, regulatory & commercial milestones along with royalties on sales of products emerges from the acquired programs Kronos to acquire the two clinical-phase assets along with the rest of Gilead’s portfolio of SYK inhibitors. The portfolio includes entospletinib, being evaluated in …

Kronos Bio to Acquire Gilead’s SYK Inhibitor Portfolio Read More »